308results about "Eye implants" patented technology

Systems and methods for delivering multiple ocular implants to reduce intraocular pressure are disclosed. The ocular implants can be implanted at multiple sites within a single human eye without requiring removal of the delivery apparatus from the eye. A system for delivering multiple ocular implants can include at least two implants preloaded within a delivery device and configured to be implanted within the eye, a metering device configured to transfer energy to the implants for delivery at selected locations within the eye, wherein the metering device is configured to meter a variable amount of energy for each implant delivery event in the eye. The system can further include an injector mechanism configured to serially engage and drive each of the implants.

Systems and methods for delivering an implant to treat an ocular disorder is disclosed. The ocular implant can include a treatment fluid that is released over the course of several days or months to treat an ocular disorder. A system for implanting and retrieving spent implants can include an implant, an external housing, and an implant assembly. The external housing can provide access to a sliding trigger. The sliding trigger can convert a portion of the implant assembly from a first configuration to a second configuration and a second configuration to a third configuration to release or retrieve an implant. In some embodiments, the implant assembly can include a collet formed from sheet metal and bent to act as a spring. The collet can have protrusions to match the profile of an implant to secure the implant during delivery. Actuation of the trigger can relieve the spring's pressure.

Disclosed herein are systems, devices, kits, and associated methods for treating conditions of the eye by reducing intraocular pressure. The system may include an ocular implant and a delivery device. The ocular implant may be implantable within Schlemm's canal to restore or maintain at least partial patency of the canal without substantially interfering with transmural or transluminal fluid flow across the canal. The delivery device may include a cannula comprising a straight proximal portion and a curved distal portion, where the curved distal portion comprises a first curve in a first direction. The delivery device may also include a positioning tool positioned at least partially within the cannula and configured to advance the ocular implant through the cannula, where the positioning tool comprises a curved distal portion biased to form a second curve in a second, different direction.

The invention discloses a preparation method of a bionic cornea stroma lens for refractive correction, which comprises the following steps: solution preparation: dissolving type I collagen in an acetic acid solution, adding a film aid, fully stirring, and centrifugally defoaming to obtain a type I collagen composite solution; the I-type collagen composite solution is poured into an assembling groove, the curvature radius of titanium metal is set to be 6.8-8.0 mm, the titanium metal serves as a working electrode material, platinum metal serves as a counter electrode material, current parameters are set according to the needed thickness of the lens blank, the density is 3.50-6.50 mA / cm < 2 >, and the thickness of the lens blank is set to be 3.50-6.50 mA / cm < 2 >; a high-transparency cornea embryo material which is uniform in curvature in all directions and similar to human cornea fiber structure arrangement is formed after electrochemical assembly and cross-linking curing, accurate cutting machining is carried out through excimer laser, a concave / convex matrix lens with the needed correction degree is obtained, the correction precision is high after cornea interlayer implantation, and the correction precision is high. And meanwhile, the compound has excellent performance in the aspects of in-vivo stability and biological safety.

A medical device for office-based / operating room bleb forming minimally invasive glaucoma surgeries. The medical device includes a proximal segment for grasping by a user, a distal segment that includes a piercing member coupled to and extending from the distal segment, wherein the piercing member is configured to contain and deliver an ocular implant into an eye tissue layer to obtain a channel, wherein the proximal segment and the distal segment being configured to couple to each other at a pivot point between an unlocked configuration and a locked configuration, and wherein in the unlocked configuration, the proximal segment and the distal segment are rotatable relative to each other about a rotation axis at the pivot point.

A method of lamellar corneal graft implantation is disclosed herein. The method includes the steps of: (i) forming one or more intrastromal incisions in a cornea of an eye of a patient; (ii) removing a cut portion of the cornea defined by the one or more intrastromal incisions from the eye of the patient; (iii) applying laser energy to a lamellar corneal graft using an excimer laser so as to modify the refractive power of the lamellar corneal graft, the lamellar corneal graft being in the form of a autologous corneal graft or a homologous corneal graft; and (iv) implanting the lamellar corneal graft into the eye of the patient in a location previously occupied by the cut portion of the cornea so as to correct the refractive power of the eye of the patient.

A system for treating an eye comprising a tissue stored within a lumen of an elongated cannula, the tissue comprises scleral, amniotic membrane, or acellular biomatrix tissue and having an elongated form factor. Related devices, systems, and methods are provided.

A surgically implanted ocular optical array that can be used in both therapeutic and diagnostic applications is described. A device configured to be implanted in an eye includes: an imaging system that receives visible light incoming to the eye; optical source generating circuitry that generates an optical signal based on the light received by the imaging system; and an optical phased array (OPA) that generates and projects an image onto a retina of the eye in which the device is implanted, the image being based on the optical signal generated by the optical source generating circuitry.

This invention discloses an ocular implant and its delivery system, comprising: a flexible substrate; multiple nanowire arrays disposed on the flexible substrate; an elastic ring disposed along the circumferential edge of the flexible substrate, the elastic ring having elastic memory and capable of returning to its original shape before deformation after deformation; and two opposing openings disposed near the edge of the flexible substrate. The nanowire array of the ocular implant of this invention can be composed of multiple materials spliced ​​together, and materials with different efficacies and photosensitive wavelengths can be selected for splicing. Therefore, personalized ocular implants can be customized according to different patient conditions to achieve a better match with the patient's fundus condition. Furthermore, the folding and opening design of the ocular implant of this invention, as well as the self-expanding property of the elastic ring, enable it to be adapted to a delivery system for positioning and minimally invasive implantation.

A device and its use in a method for changing an eye color is disclosed. The device comprises a plurality of colored intracorneal ring segments of pre-defined length, width and positioning. The method comprises forming a pair of concentric intracorneal tunnels in a mid- periphery of a cornea. The pair of concentric intracorneal tunnels comprises an inner intracorneal tunnel and an outer intracorneal tunnel. The inner intracorneal tunnel is configured to accommodate a pair of colored inner ring segments wherein each of the colored inner ring segment comprises a plurality of first fenestrations. The outer intracorneal tunnel is configured to accommodate a pair of colored outer ring segments wherein, each of the colored outer ring segment comprises a plurality of second fenestrations. Furthermore, a cross-section of the pair of colored inner ring segments and the pair of colored outer ring segments is bilamellar.

This application relates to a femtosecond laser multi-degree-of-freedom personalized reshaping method and system for intracorneal implants, belonging to the field of femtosecond laser processing technology. Utilizing the cold processing characteristics of femtosecond lasers, the intracorneal implant is individually cut and ablated to obtain the desired three-dimensional corneal shape, precisely shaping the curvature, thickness, and contour of the lens to perfectly match the patient's corneal capsule or lesion area. By leveraging the nonlinear optical effect induced at the focal point of the femtosecond laser, the stromal collagen network in the weak areas corresponding to corneal expansion can be densified through laser processing, significantly improving the local elastic modulus and resistance to deformation. In areas requiring a smooth transition with the recipient cornea or adjustment of refractive power, controllable micropores or low-density areas can be induced, appropriately reducing local stiffness, thereby achieving a spatial gradient distribution of internal mechanical properties and customizing the overall mechanical behavior and morphological stability after implantation.

A device for applying a bubble of a substance to a tissue surface, the device comprising a cannula, a distal tip at the distal end portion of the cannula, the distal tip having a bubble support surface and an exit port extending through the bubble support surface, an expansion fluid passageway extending through the cannula to the exit port, a source of an expansion fluid and an actuator therefor. In some arrangements, the distal tip can be configured to support a layer of the substance thereon over the distal port and the device can be configured such that the advancement of the expansion fluid from the fluid source through the exit port causes at least one bubble of the substance to form on the distal tip, wherein the at least a portion of the bubble can be transferred to the tissue surface to treat a defect on the tissue surface.

The present invention relates to a dental / medical device that comprises poly(dioxanone) (PDO or PDS), preferably has an absorbent synthetic film exhibiting a color from white to grey, and is applied in the medical and dental fields. The dental / medical device may have stem cells and graphene used for inducing tissue reconstruction and / or inducing tissue regeneration of bone defects and other connective tissues (such as gingiva, skin, cartilage, cornea, etc.). Further, the present invention relates to the use of the device for the related applications described above and a method for manufacturing the device.

To ensure that the implant is securely fixed until deployment and to reduce the risk of introducing undesirable particulate matter into the patient, we provide an implant with improved retention within the needle of the delivery device, which reduces the risk of retention failure based on the delivery device. [Solution] A medical implant is disclosed. The medical implant has a body having a first end having a first cross-sectional dimension, a second end having a second cross-sectional dimension, and a tapered portion extending between the first and second ends. The first cross-sectional dimension is larger than the second cross-sectional dimension. In some embodiments, the body comprises multiple layers.

The invention relates to a transport holder (1) for a receiving device for a transplant or implant, in particular for a DMEK lamella. During transport and / or storage, the transport holder (1) is arranged together with the receiving device in a container filled with a medium. The transport holder (1) has resilient means (4) at a first lateral end and, at a second lateral end opposite the first lateral end, a device (3) for gripping the transport holder. The transport holder is designed such that the resilient means (4) press the means (3) for grasping the transport holder during transport and / or storage against a lid of the container, and the means (3) for grasping the transport holder are pushed out of an opening in the container, owing to the resilient means (3), after the lid has been opened, such that the means (3) for grasping the transport holder can move outside the container and can be grasped. The invention also relates to a transport system comprising such a transport holder.

An insertion device for an ocular implant for regulating intraocular pressure includes a cannula having an internal space for receiving at least a portion of an ocular implant having a stent and an implant opening for inserting the ocular implant; a handle configured to be connected to the cannula and held by a surgeon; and a holder configured to be coupled to the handle and including a receiving portion configured to receive the stent of the ocular implant. The ocular implant insertion device appropriately fixes the stent inserted into the tube of the ocular implant in a manner attached to the insertion device, thereby preventing problems such as the stent coming out of the tube, the implant being separated from the insertion device by the stent, or the stent obscuring the surgeon's field of vision during implant implantation surgery.

A method is described of improving adhesion of an ocular implant (10) to corneal tissue by forming an implant adhesive layer (14) on the ocular implant (10), the implant adhesive layer (14) having greater adhesive strength than a rest of the implant (10). This is done by making chemical and / or physical changes on an anterior surface of the implant (10) that make the implant adhesive layer (14) more adhesive than the rest of the implant (10).

A novel multi-layered ocular implant device is provided. In some embodiments, the device is adapted to reside in the sub-Tenon space of the patient's eye. In some systems, the separate layers of the implant device will contain separate therapeutic agents, for example, two or more different agents that can deliver a desired pharmacological effect. In some preferred systems, the separate therapeutic agents in the separate device layers may provide a coordinated pharmacological effect, for example, a first layer may contain a primary therapeutic agent, and a second layer may contain a therapeutic agent that provides a supportive benefit to the primary therapeutic agent, such as reducing side effects or enhancing patient uptake of the primary therapeutic agent, or other delivery enhancement.

The application discloses a 3D printing ocular prosthesis platform, which is prepared through the following steps: S1, designing the shape of the ocular prosthesis platform and dividing the shape into regions; S2, selecting a porous structure for the ocular prosthesis platform in each region and determining the voxel size according to the connecting point parameters of the selected porous structure; S3, voxelizing and fitting each region to form a voxelized interface; S4, filling the porous structure selected in step S2 into each corresponding region to complete the modeling of the porous structure in each region; S5, connecting the connecting points on adjacent voxelized interfaces to each other and converting the connecting lines into solid rod models to complete the modeling of the interfaces; S6, merging the models obtained in steps S4 and S5 to obtain a final model of the ocular prosthesis platform; S7, 3D printing to obtain a bioceramic blank; and S8, high-temperature sintering of the blank to obtain a 3D printed ocular prosthesis platform after porcelain forming. The application can obtain a new 3D printed ocular prosthesis platform, which provides technical support for ocular prosthesis repair.

An imaging probe comprises a camera or endoscope with an external detector array, in which the probe is sized and shaped for surgical placement in an eye to image the eye from an interior of the eye during treatment. The imaging probe and a treatment probe 500 can be coupled together with a fastener or contained within a housing. The imaging probe and the treatment probe 500 can be sized and shaped to enter the eye through an incision in the cornea and image one or more of the ciliary body band or the scleral spur. The treatment probe 500 may comprise a treatment optical fiber or a surgical placement device to deliver an implant. A processor coupled to the detector can be configured with instructions to identify a location of one or more of the ciliary body band, the scleral spur, Schwalbe's line, or Schlemm's canal from the image.

This invention provides a method for encapsulating cells in microtissue. [Solution] A method for encapsulating cell microtissues includes coating a tissue scaffold stamp with an extracellular matrix compound. The method includes placing the tissue scaffold stamp on a thermoresponsive substrate and seeding a cell culture onto the tissue scaffold stamp. The cell culture forms cell patches that bind to the extracellular matrix compound. A monolayer boundary on the tissue scaffold stamp maintains expression for intercellular junctions, where the monolayer intercellular junctions are configured to express tension. The method includes removing the thermoresponsive substrate. The method includes folding the microtissue structure by suspending the microtissue in a solvent. The folded microtissue structure is recovered from the solvent and administered to a living organism.

A system for treating an eye comprising a tissue stored within a lumen of an elongated cannula, the tissue comprises scleral. amniotic membrane, or acellular biomatrix tissue and having an elongated form factor. Related devices, systems, and methods are provided.

The present technology is generally directed to an adjustable shunting system for draining fluid from a first body region to a second body region. The adjustable shunting system can include a screen assembly configured to at least partially prevent debris from entering an internal portion of the adjustable shunting system. For example, the screen can be at least partially aligned with one or more fluid inlets of the adjustable shunting system. In some embodiments, the adjustable shunting system include one or more actuators that can be actuated via energy. In such embodiments, the screen assembly can be configured such that the actuators are accessible to energy through the screen. In these and other embodiments, the screen can be at least partially cleaned of debris by applying non-invasive ablative energy to the screen.

The present disclosure relates to a support element (10) for an artificial cornea, the support element being disc-shaped and concentric with a central axis (P) and comprising: a central region (101) and a perimetral (102) region adjacent to a perimeter edge of the support element, the central region comprising a convex face (1011), a concave face (1012) opposed to each other and one central through hole (103) concentric with the central axis; wherein the perimetral region is flared, the surface of the support element is coated with silver, and at least the concave face of the support element comprises a peptide or a pharmaceutical salt thereof attached therein. The present disclosure also relates to an artificial cornea comprising the support element described.

The present disclosure discloses a bioengineered formulation comprising: (a) a modified collagen peptide having a molecular weight in the range of 20-80 kDa, and with a degree of substitution in the range of 20-75%; and (b) a modified hyaluronic acid having a molecular weight in the range of 10-100 kDa, and with a degree of substitution in the range of 20-75%. The present disclosure also discloses the bioengineered formulation comprising stem cells, or exosomes, or combinations thereof. Further, the process for preparing the bioengineered formulation is also disclosed therein. Moreover, the formulation comprising: a) exosomes selected from the group consisting of corneal stromal stem cell derived-exosomes, primed mesenchymal stem cell derived-exosomes, and naive mesenchymal stem cell derived-exosomes; and (b) a clinically approved eye drop formulation is also provided.

A method for controlling an artificial iris (100) comprises: receiving (302) a measurement of light intensity detected by a sensor (110) on or adjacent to the artificial iris (100); accessing (304) a user-specific profile based on user calibration for determining one or more user-specific thresholds of light intensity of the user-specific profile, wherein the one or more user-specific thresholds are associated with light intensities for triggering a change of light transmittance through the artificial iris (100); comparing (306) the received measurement of light intensity to the one or more thresholds in the user-specific profile; and determining (308), based on said comparing, whether to turn on or turn off one or more concentric rings (104) of liquid crystals of the artificial iris (100) for controlling an amount of light transmitted through the artificial iris (100).

A retinal ganglion cell (RGC) stimulation system for an optic nerve. The system can comprise a ground electrode, a stimulation electrode, a voltage or current source connected to both the ground electrode and the stimulation electrode and configured to stimulate the stimulation electrode with an electrical waveform having a first voltage and a first current, and a controller connected to the voltage or current source and controlling the first voltage and the first current of the electrical waveform.

The invention relates to a method for generating control data for correcting the refraction of an eye (2) by corneal modification, comprising receiving data about a refraction correction requirement of the eye (2), determining, on the basis of the refraction correction requirement, an additive refraction change value by means of an implant (26) to be inserted into the cornea (17), determining a subtractive refraction change value by means of a lenticule (21) to be removed from the cornea (17), wherein the additive refraction change value together with the subtractive refraction change value results in the refraction correction requirement, calculating a lenticule (21) to be isolated in the cornea (17) on the basis of the subtractive refraction change value such that the lenticule (21) is designed to effect the subtractive refraction change value by being removed from the cornea (17), and calculating a cutting area (22, 23) such thatthat it isolates the lenticule (21) in the cornea (17) and at the same time defines a chamber for the implant (26) to be inserted, and generating data describing the cutting surface (22, 23).